AAV9-SMN1 (named Zolgensma®) has been approved for intravenous injection for spinal muscular atrophy (SMA) patients; nevertheless, its efficacy and safety data from anti-AAV9 antibody-positive patients are absent. Here, SMN1 is linked to proximal spinal muscular atrophy.